Publication: Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers
Issued Date
2018-06-01
Resource Type
ISSN
18729096
01663542
01663542
Other identifier(s)
2-s2.0-85045462667
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antiviral Research. Vol.154, (2018), 58-65
Suggested Citation
Tatsuhiko Ozawa, Hideyuki Masaki, Tomohiko Takasaki, Ikuko Aoyama, Takahiro Yumisashi, Atsushi Yamanaka, Eiji Konishi, Yoh Ohnuki, Atsushi Muraguchi, Hiroyuki Kishi Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers. Antiviral Research. Vol.154, (2018), 58-65. doi:10.1016/j.antiviral.2018.04.011 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46011
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers
Abstract
© 2018 Elsevier B.V. West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4–14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses.